A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

August 28, 2018

Primary Completion Date

July 22, 2022

Study Completion Date

July 22, 2022

Conditions
CancerPediatric Solid TumorPediatric AMLPediatric ALL
Interventions
DRUG

PEG- BCT-100

PEGylated recombinant human arginase 1

Trial Locations (14)

Unknown

Women's & Children's Hospital, Adelaide

Queensland Children's Hospital, Brisbane

Royal Children's Hospital Melbourne, Melbourne

Perth Children's Hospital, Perth

Children's Hospital Westmead, Sydney

Sydney Children's Hospital, Sydney

Princes Maxima Centrum, Utrecht

Birmingham Children's Hospital, Birmingham

Bristol Royal Hospital for Children, Bristol

Addenbrookes Hospital, Cambridge

Royal Hospital for Children, Glasgow

Leeds Children's Hospital, Leeds

Royal Manchester Children's Hospital, Manchester

Royal Marsden Hospital, Sutton

All Listed Sponsors
lead

University of Birmingham

OTHER

NCT03455140 - A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) | Biotech Hunter | Biotech Hunter